A review of postmarket safety studies by the US Food and Drug Administration (FDA) has found no significant increase in risk for serious asthma-related outcomes when a long-acting β-agonist (LABA) is ...

The four trials also assessed efficacy of the ICS/LABA products. Based on a review of four clinical safety trials, the Food and Drug Administration (FDA) has concluded that medications that contain ...

Evidence is lacking, however, to support the combination therapy for mortality (moderate-quality evidence) and exacerbations (low-quality evidence). Tiotropium + LABA/ICS did not increase adverse ...

Patients with chronic obstructive pulmonary disease (COPD) have multiple breathing problems and, at the more severe stages, experience acute exacerbations of COPD up to three times annually. Because ...

Changing patients from an inhaled corticosteroid (ICS)/long-acting β agonist (LABA) inhaler and long-acting muscarinic agonist (LAMA) inhaler to a LAMA/LABA inhaler and a separate ICS inhaler did not ...

(RTTNews) - GlaxoSmithKline plc (GSK, GSK.L) today said that it has received approval by the US Food and Drug Administration of labelling changes to remove the boxed warning from inhaled ...

Surveyed MCOs Express Greater Uncertainty Regarding the Use of Boehringer Ingelheim's Combivent for COPD Than They Do for the Use of Fixed-Dose LABA/ICS Combination Inhalers, According to a New Report ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved updates to the SYMBICORT ® (budesonide ...

Developing a new molecular entity is a lengthy, expensive and high-risk endeavour. Reformulating drugs that have been proven to be safe and effective into fixed-dose combination (FDC) products ...

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...

Asthma management guidelines advocate a stepwise approach to asthma therapy, including the addition of a long-acting bronchodilator to inhaled steroid therapy at step 3. This is almost exclusively ...